DNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes. In an interview with Targeted Oncology, Rutika Mehta, MD, ...
Clinicians have long relied on clinical risk factors, imaging, and pathology to guide cancer surveillance and adjuvant treatment. However, even after curative-intent surgery and definitive therapy, ...
Rapid Novor Inc., a Canadian biotechnology leader, announced today that its diagnostic laboratory has received a provisional license from the Ontario Ministry of Health (MOH) for its EasyM® assay, ...
Myriad Genetics will present new data on its Precise MRD test for renal cell carcinoma at the AACR Annual Meeting. Myriad Genetics, Inc. announced that it will present new clinical data on its Precise ...
Molecular residual disease (MRD) testing detects cancer recurrence months before traditional imaging Labcorp MRD tests now monitor recurrence risk across stage I–III breast cancer, stage I–IIIA ...
The Precise MRD test is Myriad’s tumor-informed circulating tumor DNA (ctDNA) assay designed to support longitudinal monitoring during cancer treatment. Using whole-genome sequencing to create a ...
Hans Lee, MD, explores how minimal residual disease (MRD) testing guides treatment decisions for multiple myeloma and highlights the value of patient preferences. Minimal residual disease (MRD) ...
CURE spoke with a provider and a survivor about the potential power of minimal residual disease testing. Minimal residual disease, or MRD, testing may have the potential to offer peace of mind to ...
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are ...
1yon MSN
Adaptive Biotechnologies targets $1,300 ASP for MRD tests in 2025 driven by pricing improvements
CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year.
In the rapidly shifting landscape of multiple myeloma treatment, the roadmap for a patient diagnosed in 2026 looks vastly different than it did even a decade ago. In a recent interview with CURE, Dr.
Allogene Therapeutics (NASDAQ:ALLO) used its fourth-quarter 2025 conference call to outline what management described as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results